Out of 7 analysts covering Imprivata Inc (NYSE:IMPR), 7 rate it “Buy”, 0 “Sell”, while 2 “Hold”. This means 78% are positive. Imprivata Inc was the topic in 15 analyst reports since August 17, 2015 according to StockzIntelligence Inc. Below is a list of Imprivata Inc (NYSE:IMPR) latest ratings and price target changes.
03/11/2015 Broker: Barclays Capital Rating: Overweight Old Target: $22.00 New Target: $15.00 Target Down
03/11/2015 Broker: Leerink Swann Rating: Outperform Old Target: $20.00 New Target: $17.00 Target Down
03/11/2015 Broker: Piper Jaffray Rating: Old Target: $23.00 New Target: $19.00 Target Down
03/11/2015 Broker: Oppenheimer Rating: Outperform Old Target: $20.00 New Target: $17.00 Maintain
03/11/2015 Broker: Topeka Capital Markets Rating: Buy Old Target: $20.00 New Target: $17.00 Maintain
15/10/2015 Broker: Barclays Capital Rating: Overweight New Target: $22.00 Target Down
15/10/2015 Broker: Leerink Swann Rating: Outperform Old Target: $23.00 New Target: $20.00 Target Down
15/10/2015 Broker: William Blair Old Rating: Outperform New Rating: Market Perform Downgrade
15/10/2015 Broker: Topeka Capital Markets Rating: Buy Old Target: $24.0 New Target: $20.0 Maintain
15/10/2015 Broker: Stifel Nicolaus Rating: Buy Old Target: $24 New Target: $20 Maintain
The stock decreased 1.00% or $0.12 on March 24, hitting $11.93. About 61,383 shares traded hands. Imprivata Inc (NYSE:IMPR) has declined 44.59% since August 19, 2015 and is downtrending. It has underperformed by 42.49% the S&P500.
Imprivata, Inc. is a provider of healthcare information technology) IT security solutions. The company has a market cap of $296.58 million. The Company’s solutions provide authentication management, access to patient information and communications technologies to the healthcare industry. It currently has negative earnings. The Company’s solutions include Imprivata OneSign, Imprivata Cortext and Imprivata Confirm ID.
The institutional sentiment decreased to 1.85 in Q3 2015. Its down 1.36, from 3.21 in 2015Q2. The ratio worsened, as 7 funds sold all Imprivata Inc shares owned while 20 reduced positions. 23 funds bought stakes while 27 increased positions. They now own 17.12 million shares or 12.19% more from 15.26 million shares in 2015Q2.
Murphy Michael R holds 3.15% of its portfolio in Imprivata Inc for 515,814 shares. Tamarack Capital Management Llc owns 1.43 million shares or 3.01% of their US portfolio. Moreover, Harvey Partners Llc has 1.69% invested in the company for 153,000 shares. The California-based Wall Street Associates has invested 1.23% in the stock. Granite Point Capital Management L.P., a Massachusetts-based fund reported 80,046 shares.
Since March 31, 2015, the stock had 0 insider purchases, and 4 selling transactions for $326,332 net activity. Kalowski Jeffrey sold 1,000 shares worth $18,006. Brigiotta Thomas W. sold 5,000 shares worth $83,379. Ting David sold 8,000 shares worth $138,591. Hussain Omar sold 15,000 shares worth $299,667. The insider Shaw Christopher A sold 4,000 shares worth $79,959.
Imprivata Inc - Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with MarketBeat.com’s FREE daily email newsletter.
